NASDAQ:FBIO - Fortress Biotech, Inc.
$1.30
 $-0.07
-5.11%
4:00PM EDT
2019-07-22
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  FBIO     avg for
industry  
  avg for
sector  
42 stocks weight:  8. 95   217. 37   399. 45  
42 stocks rank:  3. 84 K 1. 27 K 716. 99  
# analyst opinions:  2. 00   13. 21   13. 71  
mean recommendation:  2. 00   2. 10   2. 04  

quick ratio:  2. 69   5. 49   1. 88  
current ratio:  2. 79   5. 87   2. 36  

target price low:  4. 00   83. 44   114. 90  
target price avg:  2. 39   106. 20   137. 90  
target price high:  1. 10   132. 30   158. 97  
1-yr high:  2. 53   111. 86   142. 57  
last close:  1. 37   86. 79   125. 44  
50-day avg:  1. 67   86. 68   122. 63  
200-day avg:  1. 52   89. 22   121. 38  
1-yr low:  0. 57   69. 78   100. 51  
volume:  372. 22 K 2. 62 M 3. 43 M
50-day avg volume:  435. 02 K 3. 20 M 4. 16 M
200-day avg volume:  582. 78 K 2. 99 M 4. 75 M

1-day return:  8. 73 % -1. 30 % -0. 99 %
this week return:  -11. 04 % 0. 45 % -0. 20 %
12-wk return:  -17. 96 % 0. 94 % 4. 84 %
52-wk return:  -50. 20 % -1. 30 % 10. 55 %

enterprise value (EV):  107. 12 M 45. 10 B 122. 38 B
market cap:  89. 37 M 38. 96 B 108. 40 B
EBITDA:  -115. 99 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  -0. 92   5. 38   11. 93  
enterprise/revenue (EV/R):  3. 90   57. 92   10. 21  
total revenue:  27. 46 M 9. 91 B 39. 98 B
total debt:  109. 35 M 10. 90 B 17. 48 B
debt/equity:  215. 65   57. 18   120. 05  
net income (common):  -52. 68 M 2. 07 B 4. 05 B

shares outstanding:  65. 23 M 538. 09 M 1. 24 B
shares:  39. 60 M 548. 00 M 1. 22 B
shares short:  2. 86 M 10. 98 M 11. 87 M
shares short prior month:  2. 73 M 9. 32 M 12. 05 M
short ratio:  6. 10   5. 60   3. 34  
short % of float:  6. 68 % 6. 48 % 2. 64 %
total cash/share:  1. 86   10. 98   9. 19  
total cash:  121. 49 M 5. 93 B 6. 10 B
free cash flow:  -79. 27 M 2. 92 B 4. 55 B
operating cash flow:  -96. 33 M 3. 80 B 5. 78 B

book value:  0. 33   13. 35   27. 45  
price/book:  4. 15   4. 60   8. 78  
gross profits:  20. 76 M 7. 44 B 36. 13 B
operating margins:  -431. 36 % -308. 40 % -28. 55 %
EBITDA margins:  0. 00 % 13. 17 % 23. 38 %
profit margins:  -224. 86 % 10. 44 % 14. 18 %
gross margins:  76. 19 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -1. 38   2. 10   4. 23  
forward EPS:  -1. 74   3. 45   7. 10  
P/E:  -0. 99   1. 90   32. 10  
forward P/E:  -0. 79   6. 46   15. 47  
PE/G:  -0. 10   0. 70   -0. 54  
growth:  9. 70 % 265. 63 % 79. 11 %
earnings high:  -0. 40   0. 89   1. 68  
earnings avg:  -0. 46   0. 70   1. 57  
earnings low:  -0. 52   0. 46   1. 46  
revenue high:  7. 84 M 2. 57 B 11. 07 B
revenue avg:  7. 51 M 2. 51 B 10. 91 B
revenue low:  7. 17 M 2. 45 B 10. 73 B
return on assets:  -31. 80 % -2. 34 % 5. 28 %
return on equity:  -140. 17 % -90. 08 % 133. 53 %
revenue growth:  9. 70 % 265. 25 % 73. 68 %
revenue/share:  0. 61   12. 72   60. 04  

beta (1yr vs S&P500):  1. 64   1. 27   0. 91  
sharpe (1yr):  0. 04   0. 16   0. 77  

held % insiders:  28. 76 % 6. 06 % 3. 29 %
held % institutions:  12. 22 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : FBIO
.    101.105 =       101.105 :: --> INITIAL WEIGHT <--
.     - 1.38 =        99.725 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 1.975 =       196.936 :: P/E factor
.    x 1.768 =       348.183 :: PE/G factor
.    x 1.581 =       550.369 :: beta factor
.     x 0.65 =       357.656 :: sharpe factor
.    x 2.475 =       885.304 :: current ratio factor
.    x 1.262 =      1117.051 :: quick ratio factor
.    x 1.079 =      1205.139 :: short ratio factor
.    x 1.222 =      1472.312 :: revenue growth factor
.    x 1.067 =      1571.493 :: EV/R factor
.    x 1.051 =      1651.321 :: price-to-book factor
.    x 0.728 =      1201.923 :: debt-to-revenue factor
.    x 1.665 =      2000.862 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =      4243.415 :: sector+industry 1-year gains factor
.    x 1.009 =      4283.422 :: industry 12-weeks return factor
.    x 1.308 =      5602.239 :: industry 2-weeks return factor
.      x 1.1 =      6160.512 :: 50-day avg > 200-day avg
.    x 0.961 =      5920.851 :: "drift" penalty 2 days ago
.    x 0.956 =       5659.31 :: "drift" penalty 4 days ago
.    x 0.983 =      5564.644 :: "drift" penalty 5 days ago
.    / 2.209 =      2518.857 :: overall "drift" factor
.    x 0.864 =      2177.433 :: largest single-day jump factor
.    x 0.063 =       137.725 :: low price factor
.    x 0.694 =        95.523 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.838 =        80.083 :: forward EPS factor
.    x 0.941 =        75.379 :: forward P/E factor
.    x 1.185 =        89.302 :: industry recommendation factor
.    x 2.098 =       187.371 :: company recommendation factor
.    x 1.003 =       187.889 :: factor historical industry gain for week 29
.   x 10.774 =       2024.34 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =         6.708 :: reduced for readability
.    + 2.241 =         8.949 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                      8.949 :: FINAL WEIGHT for NASDAQ:FBIO


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org